Invitrogen™ CD153 Monoclonal Antibody (RM153), PE, eBioscience™, Invitrogen™

Beschreibung

Description: The RM153 monoclonal antibody reacts with mouse CD153 (CD30 ligand). This 40 kDa cell surface receptor, a type II transmembrane protein, is a member of the TNF superfamily. Interaction of CD30 with CD153 plays an important role in T cell activation/costimulation. Expression of CD153 on T cells does not appear to require costimulation through CD28 and is upregulated via TCR engagement and peaks 24-48 hours after activation. Signaling through CD153 is important in costimulation of pre-activated T cells. Applications Reported: The RM153 antibody has been reported for use in flow cytometric analysis. Applications Tested: The RM153 antibody has been tested by flow cytometric analysis of activated mouse splenocytes. This can be used at less than or equal to 0.125 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and the IL4 receptor.